Global Solutions For Infectious Diseases is located in Lafayette, CA. The organization was established in 2005. According to its NTEE Classification (H81) the organization is classified as: AIDS Research, under the broad grouping of Medical Research and related organizations. As of 12/2021, Global Solutions For Infectious Diseases employed 6 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Global Solutions For Infectious Diseases is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Global Solutions For Infectious Diseases generated $1.3m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 7 years, the organization has seen revenues fall by an average of (3.0%) each year. All expenses for the organization totaled $1.1m during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (7.0%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
THE MISSION OF GSID IS TO EXPAND THE DEVELOPMENT OF LOW-COST EFFECTIVE TOOLS FOR THE DIAGNOSIS AND PREVENTION OF INFECTIOUS DISEASES AFFLICTING LESS DEVELOPED COUNTRIES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
AIDSVAX HIV VACCINE PROGRAM:DURING 2021, NO ACTIVITIES WERE CONDUCTED RELATED TO DIAGNOSTICS OR GLOBAL HEALTH CONSULTING. GSID'S PRIMARY FOCUS WAS IN THE AREA OF HIV VACCINE DEVELOPMENT. NO ACTIVITIES WERE CONDUCTED RELATED TO DIAGNOSTICS OR GLOBAL HEALTH CONSULTING. IN THE HIV AIDSVAX PROGRAM WERE FOCUSED ON THE CLINICAL TRIALS SPONSORED AND FUNDED BY THE US MILITARY HIV PROGRAM HENRY M. JACKSON FOUNDATION/MHRP), THE HIV VACCINE TRIALS NETWORK (HIH/NIAID/HVTN) AND IMPERIAL COLLEGE LONDON.DURING 2021, THE PREPVACC CLINICAL TRIAL WAS INITIATED AND FULLY OPERATIONAL AT ALL FOUR STUDY TRIAL SITES LOCATED IN UGANDA, TANZANIA AND SOUTH ARICA. THIS TRIAL IS SPONSORED BY IMPERIAL COLLEGE LONDON AND IS FUNDED BY THE EUROPEAN DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP), AN AGENCY OF THE EUROPEAN UNION. VOLUNTEER ENROLLMENT IS SCHEDULED FOR COMPLETION BY THE END OF 2022 AND THE STUDY WILL BE COMPLETED BY THE END OF 2024.GSID ACCOMPLISHED THE FOLLOWING IN 2021: 1) CONDUCTED PRODUCT STABILITY TESTING OF ITS PROPRIETARY VACCINE CANDIDATE, AIDSVAX B/E; 2) PREPARED REQUIRED INTERNAL PRODUCT REPORTS AND REGULATORY SUBMISSIONS; 3) CO-AUTHORED PEER-REVIEWED PUBLICATIONS; AND 4) UPDATE ITS PUBLIC WEBSITE.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Carter A Lee Executive Director | OfficerTrustee | 40 | $183,000 |
Vineeta G Gulati Director, Clinical Ops & R | 20 | $141,000 | |
Faruk M Sinangil Board Member | Trustee | 20 | $100,500 |
Dr Seung-Il Shin Board Member | Trustee | 1 | $0 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $1,338,688 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,338,688 |
Total Program Service Revenue | $0 |
Investment income | $0 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $1,338,688 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $630,992 |
Compensation of current officers, directors, key employees. | $63,099 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $0 |
Pension plan accruals and contributions | $22,716 |
Other employee benefits | $90,050 |
Payroll taxes | $46,450 |
Fees for services: Management | $1,815 |
Fees for services: Legal | $20,898 |
Fees for services: Accounting | $0 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $115,903 |
Advertising and promotion | $0 |
Office expenses | $8,065 |
Information technology | $1,786 |
Royalties | $0 |
Occupancy | $0 |
Travel | $0 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $0 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $0 |
Insurance | $72,948 |
All other expenses | $0 |
Total functional expenses | $1,059,111 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $491,976 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $117,163 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $0 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $609,139 |
Accounts payable and accrued expenses | $0 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $5,640 |
Total liabilities | $5,640 |
Net assets without donor restrictions | $0 |
Net assets with donor restrictions | $603,499 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $609,139 |
Over the last fiscal year, we have identified 1 grants that Global Solutions For Infectious Diseases has recieved totaling $17,600.
Awarding Organization | Amount |
---|---|
International Vaccine Institute PURPOSE: PROGRAM SERVICE | | $17,600 |
Organization Name | Assets | Revenue |
---|---|---|
Global Strategies Albany, CA | $3,042,187 | $1,030,884 |
Global Solutions For Infectious Diseases Lafayette, CA | $609,139 | $1,338,688 |
Simmaron Research Inc Incline Village, NV | $221,950 | $483,746 |
Southern Nevada Aids Research & Education Society Las Vegas, NV | $3,951 | $206,563 |
Mama Makeka House Of Hope Fresno, CA | $110,077 | $0 |
Seeds Of Empowerment Corporation San Jose, CA | $11,517 | $0 |
Isv Foundation Bellflower, CA | $64,653 | $0 |